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Background: Gastroesophageal reﬂux disease (GERD) is known as a common comorbidity of asthma and
chronic cough. The impact of GERD symptoms on cough-speciﬁc quality of life (QoL) in patients with
asthmatic cough is poorly understood. The aim of this study is to determine the association of GERD
symptoms with cough-speciﬁc quality of life in patients with cough variant asthma (CVA) using the
Leicester Cough Questionnaire (LCQ).
Methods: A total of 172 consecutive patients (121 females) with mean cough duration of 45.1 months
(range 2e480 months) completed the Japanese version of the LCQ. The Frequency Scale for the Symp-
toms of Gastroesophageal reﬂux was administered to assess symptoms of acid-reﬂux and dysmotility. A
range of clinical variables that may determine cough-speciﬁc QoL (LCQ) were estimated.
Results: The mean LCQ scores was 12.9 (SD 3.5), consistent with severe impairment in QoL. Female
gender, symptoms of gastroesophageal dysmotility, sensitization to allergens (house dust and Japanese
cedar pollen) and the number of sensitized allergens were associated with lower LCQ scores (i.e.
impaired cough-speciﬁc QoL) in univariate regression analysis. Acid-reﬂux symptoms, airway hyper-
responsiveness, fractional exhaled nitric oxide, and sensitization to molds were unrelated to the LCQ
score. After adjustment for gender, symptoms of gastroesophageal dysmotility was the only signiﬁcant
determinant of impaired cough-speciﬁc QoL accounting for 23% of the variance.
Conclusions: Cough-speciﬁc QoL is severely impaired in patients with CVA. Symptoms of gastroesoph-
ageal dysmotility are an independent predictor of cough-speciﬁc QoL of patients with CVA.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Cough is a very common complaint for which patients seek
medical attention. Although most cases are acute and self-
limiting, some patients develop chronic cough that persists for 8
weeks or longer and are referred to specialists because chronic
cough is associated with impairment of health-related quality of
life (QoL).1 Cough variant asthma (CVA) is considered one of the
most common causes of chronic cough worldwide.2e6 The factors
that contribute to the impairment of cough-speciﬁc QoL in pa-
tients with CVA or asthmatic cough are only partly understood. In
studies of patients with asthma, cough-speciﬁc QoL assessed with
the Leicester Cough Questionnaire (LCQ) was associated with
objective cough counts,7 but not with pathophysiological param-
eters such as airway hyperresponsiveness (AHR), airway inﬂam-
mation and pulmonary function.8 The impact of other potentially
relevant factors on cough-speciﬁc QoL such as gastroesophageal
reﬂux disease (GERD) and atopy have not been studied. The
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identiﬁcation of important comorbidities may lead to a more
targeted therapeutic approach.
GERD is another common cause of chronic cough.9 GERD co-
exists frequently in difﬁcult-to-treat patients with asthma and
CVA.10,11 In a survey of a general population, symptoms of regur-
gitation and irritable bowel syndrome, but not heart burn, were
signiﬁcantly associated with the presence of chronic cough, sug-
gesting that gastroesophageal dysmotility may be more impor-
tantly associated with chronic cough than acid reﬂux.12
The Frequency Scale for the Symptoms of GERD (FSSG) is a
questionnaire which has been developed for not only diagnosis but
also evaluation of the treatment response of GERD.13 It covers the
12most common symptoms of GERD consisting of 2 domains: acid-
reﬂux symptoms and dysmotility symptoms. Previous study has
demonstrated association of endoscopic13 and manometric14 ﬁnd-
ings with FSSG scores. Thus, the FSSG could be a simple and useful
tool to assess symptoms of GERD in clinical and research ﬁelds of
respiratory medicine.15e18
The aim of this study was to determine the impact of GERD
symptoms on cough-speciﬁc QoL in patients with CVA. This
involved the development and validation of a Japanese version of
the LCQ.
Methods
Patients
Among patients who visited the Asthma and Chronic Cough
Clinic of Kyoto University Hospital between July 2009 and
December 2012, 260 patients were newly diagnosed as having CVA.
This was according to the Japanese Respiratory Society guidelines
for management of cough on the basis of isolated cough persisting
for 8 weeks or longer without dyspnea or wheezing, no remarkable
ﬁndings on chest X-ray and auscultation on the lung, presence of
AHR to inhaled methacholine and improvement of coughing in
response to inhaled short-acting b2 agonists (SABA).3 Double-blind
controlled study conducted by Irwin et al. clearly demonstrated
that improvement of cough with bronchodilators such as SABAwas
the essential diagnostic feature of CVA.19 The patients had no his-
tory of typical asthma with wheezing, or upper respiratory infec-
tion within the previous 8 weeks. A total of 88 patients were
excluded from the study because they were current smokers or ex-
smokers who had smoked within 6 months or had a smoking
history of more than 10 pack-years, failed to complete the LCQ or
the FSSG or had been taking inhaled corticosteroids within 4 weeks
prior to the ﬁrst visit. As a result, the study involved 172 patients
(121 females) in a cross-sectional design. This study was approved
by the ethics committee of Kyoto University (Approval number
E715), and was supported in part by a Grant-in-Aid for Scientiﬁc
Research from the Ministry of Education, Culture, Sports, Science
and Technology of the Japanese government (23591117). Written
informed consent was obtained from all participants.
Measurements of clinical indices
Patients underwent spirometry and measurement of AHR,
fractional exhaled nitric oxide (FeNO), blood eosinophil counts and
serum levels of total/speciﬁc IgE. They also ﬁlled in the LCQ and the
FSSG questionnaires. Spirometry was performed using a Chest-
Graph HI-701 spirometer (Chest MI Corp, Tokyo, Japan) according
to the current guidelines.20 AHR was examined by a continuous
methacholine inhalation with simultaneous measurement of res-
piratory resistance (Rrs) (cmH2O/L/s) (Astograph; Chest, Tokyo,
Japan) as described previously.21 FeNO levels were measured at an
expiratory ﬂow rate of 50 mL/s with a chemiluminescence analyzer
(NOA 280; Sievers, Boulder, CO, USA) according to current guide-
lines.22 Speciﬁc IgE titers were measured against nine allergens:
house dust, Dermatophagoides pteronyssinus, Japanese cedar pollen,
mixed gramineae pollens (orchard grass, sweet vernal grass,
bermuda grass, timothy, reeds), mixed weed pollens (ragweed,
mugwort, goldenrod, dandelion, oxeye daisy), mixed moulds
(Penicillium, Cladosporium, Aspergillus, Candida, Alternaria), cat
dander, dog dander, and Trichophyton rubrum) (ImmunoCAP®;
Phadia K.K., Tokyo, Japan). Speciﬁc IgE levels 0.35 UA/mL were
considered positive. If patients had one or more sensitized aller-
gens, they were considered as having atopic predisposition.
Measurement of cough-speciﬁc QoL and cough severity
Cough-speciﬁc QoL was evaluated using the LCQ, which was
translated into Japanese. The Leicester Cough Questionnaire (LCQ)
is a validated questionnaire that evaluates the degree of chronic
cough and reﬂects cough-speciﬁc QoL.23 It consists of 19 questions
covering 3 subdomains (physical, social, and psychological); the
total scores range from 3 to 21, with the higher scores indicating
better QoL.23 We performed forward and backward translation
according to The International Quality of Life Assessment proto-
col.24 Brieﬂy, two Japanese specialists of cough, both of who are
familiar with English, produced the Japanese version of the LCQ
(ﬁrst forward translation). Followed by ﬁrst backward translation
conducted by a professional English editor who belongs to Forte
corporation (Tokyo, Japan), the original developer (SSB) checked it
and pointed out problems. Based on the original developer's
comments, some parts of the original questionnaire were retrans-
lated into Japanese (second version of the forward translation).
After this version was re-translated into English again, original
developer rechecked it and conﬁrmed that intended questions did
not change.23,24 The Japanese translators including one of the
present authors (AN) were authorized to do the translation of the
LCQ and to have the copyright for the Japanese version of LCQ by
the original author.23 Previous studies demonstrated signiﬁcant
correlations between the LCQ and objective cough monitoring.7,25
The use of LCQ questionnaire was permitted by the original
developer (SSB)
In addition to the LCQ, cough visual analog scales (VAS) and
numeric cough scores,26 both of which have been used to measure
the severity and frequency of cough, have been also determined
since January 2012. Cough VAS is a 100 mm-line scale where its
length represents the severity of cough7,25 (i.e. 0 mm ¼ no cough,
100 mm ¼ worst cough imaginable). Numeric cough scores were
developed by Hsu et al.26 ranging from 0 to 5 reﬂect the cough
frequency and severity in the daytime and nighttime.7,25,26 Lower
score indicates less severe or less frequent coughing.
The GERD questionnaire
GERD symptoms were evaluated using the original version of
self-reporting FSSG questionnaire originally developed in Japan,13
which was validated on the basis of endoscopic ﬁndings. It con-
sists of the most prevalent 12 symptoms chosen from 50 symptoms
of GERD. Each symptom was scored according to its frequency as
follows: 0 ¼ never, 1 ¼ occasionally, 2 ¼ sometimes, 3 ¼ often, and
4 ¼ always.13 The maximum scores of the acid-reﬂux symptoms
domain (comprised of 7 items), dysmotility symptoms domain
(comprised of 5 items), and the total of both were 28, 20, and 48
points, respectively.13 A previous study demonstrated that esoph-
ageal peristaltic pressures during dry swallow which were
measured using a manometry catheter via a transnasal endoscope
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showed a negative correlation with FSSG scores.14 Permission for
use of the FSSG was obtained from Dr. Kusano, the original devel-
oper of the FSSG.
Statistical analysis
Statistical analyses were performed using JMP 9.0 (SAS Institute
Inc., Tokyo, Japan). Data are presented as means (SD). The effect of
clinical variables on the LCQ scores was estimated using univariate
regression analysis. When data were not distributed normally, they
were log-transformed. Sex, smoking status, atopic predisposition,
and sensitized speciﬁc antigens were analyzed as dichotomous
variables. Multivariate regression analysis was used to examine
whether individual factors contributed independently to the LCQ.
Variables with p  0.10 on the univariate analysis were involved in
themultivariate analysis. Total score of the FSSGwas excluded from
multivariate analysis because of strong correlation with
dysmotility-like dyspepsia symptoms score of the FSSG. Correla-
tions between the LCQ and cough visual analog scales or numeric
cough scores were conducted using Pearson's correlation test in a
subset of patients (n ¼ 54). A p value  0.05 was considered sig-
niﬁcant. To conﬁrm the reliability of the LCQ translated into Japa-
nese, Cronbach's a coefﬁcient, an index of reliability, was
calculated.27 Alpha coefﬁcient ranges from 0 to 1 and its value
represents the degree to internal consistency within an instrument.
Cronbach's a coefﬁcient of 0.7 or greater is generally considered to
guarantee an acceptable reliability.27
Results
Patients' characteristics
The characteristics of the 172 patients with CVA are presented in
Table 1. Overall, 70% of patients were female, and 30 patients were
ex-smokers with a median smoking history of 3.9 (3.3) pack-years.
Cough duration ranged from 2 to 480 months. The results of
spirometry, AHR, and FeNO are also shown in Table 1.
The evaluation of the reliability and validity of the Japanese version
of the LCQ
The Cronbach's a coefﬁcient for total scores of the LCQ examined
for the whole 172 patients was 0.91 and that for the three domains
ranged from 0.79 to 0.85, indicating a good internal consistency for
the Japanese version of the LCQ. To assess the construct validity
between the Japanese version of the LCQ and other standard in-
struments utilized to assess cough severity and frequency, corre-
lations of the Japanese version of the LCQ with cough VAS and
numeric scores were determined in 54 patients. We found signiﬁ-
cant correlations between the LCQ scores and cough VAS or
numeric cough scores (Fig. 1).
Measurements of the LCQ and the FSSG
The mean LCQ and FSSG scores are given in Table 1. The average
of total, physiological, social and psychological scores of the LCQ
were 12.9 (3.5), 4.6 (1.0), 4.1 (1.2) and 4.2 (1.5), respectively. The
total score was as low as those reported in previous studies of
chronic cough (12.0e14.9),28e30 indicating that our patients with
CVA had impaired health status due to their coughing.
According to the FSSG scores, acid-reﬂux symptoms were
observed in 57 patients (33%). Meanwhile, 73 patients (42%) com-
plained of dysmotility symptoms.
Relationships between the LCQ and clinical variables
Univariate regression analysis showed that female gender,
increased dysmotility symptoms domain and total FSSG scores,
sensitization to house dust and Japanese cedar pollen, and
increased number of sensitized allergens were associated with
lower LCQ scores (Table 2). Lower FEV1 was marginally associated
with the impairment of cough-speciﬁc QoL. Other variables, such as
acid-reﬂux symptoms, AHR, FeNO50, and sensitization to molds
were unrelated to the LCQ scores. Multivariate regression analysis
showed that the LCQ scores was independently associated with
female gender and higher dysmotility symptoms scores (Table 3).
After the adjustment for gender, we found that dysmotility symp-
toms was solely associated with the impairment of cough-speciﬁc
QoL (Table 4).
Among the whole 172 patients, 24 patients were treated with
proton pump inhibitors and/or prokinetic therapy, and 10 patients
reported a reduction in cough, veriﬁed by review of case notes.
When these 10 patients who responded to GERD therapy in addi-
tion to CVA were removed from analysis, dysmotility symptoms
still remained a signiﬁcant predictor of the impairment of cough-
speciﬁc QoL together with female gender (Table 5).
Discussion
The present study demonstrated that cough-speciﬁc QoL is
severely impaired in patients with CVA. We also report for the ﬁrst
time to our knowledge, that GERD symptoms, particularly dysmo-
tility symptoms, are associated with impaired cough-speciﬁc QoL
measured by the LCQ. Meanwhile, there were no relationships
between the LCQ scores and spirometry, AHR, or FeNO.
Table 1
Patients' characteristics.
Gender, females/males 121/51
Age, years old 51.6 ± 17.5
Disease duration, months 45.1 ± 81.6
Body mass index, kg/m2 22.5 ± 3.4
Smoking, never/ex-smoker 142/30
FEV1, L 2.73 ± 0.9
%FEV1, % predicted 109.6 ± 20.6
FEV1/FVC, % 81.5 ± 7.8
Fractional exhaled nitric oxide at 50 ml/s, ppb 25.4 ± 17.1
AHR (Dminy, unit) 8.6 ± 11.7
Blood eosinophil, mL 179 ± 163
Total IgE, IU/ml 65 (0e5400)
Antigen speciﬁc IgE (positive), % e
Mixed gramineaes pollens 26.7
Mixed moulds 11.6
Mixed weed pollens 9.3
House dust 30.2
Dermatophagoides pteronyssinus 30.2
Japanese cedar pollen 48.8
Dog dander 9.9
Cat dander 8.7
Trichophyton rubrum 10.5
Sensitization to aeroallergen at least 1 or more, % 61.0
Number of sensitized allergens 1.8 ± 2.2
The Leicester Cough Questionnaire, Total scores 12.9 ± 3.5
FSSG, total scores 6.5 ± 6.8
Reﬂux-related symptoms domain 3.6 ± 3.7
Dysmotility symptoms domain 2.9 ± 3.6
Cough visual analog scales, mmz 51.5 ± 21.4
Numeric cough scores at daytimez 2.8 ± 0.9
Numeric cough scores at nighttimez 1.5 ± 1.1
Data are expressed as means ± SD except for median (range) for serum total IgE
levels.
y Dmin: the cumulative dose of inhaled methacholine at the inﬂection point at
which Rrs began to increase.
z n ¼ 54. FSSG, the Frequency Scale for the symptoms of gastroesophageal reﬂux.
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Relationships between chronic cough and GERD have been well
known.31 Roka et al. showed that 18% of patients with GERD had
chronic respiratory complications, of whom 75% complained of
chronic cough.32 Two mechanisms are assumed for the chronic
cough caused by GERD: microaspiration of gastric contents into the
proximal airways, and vagally-mediated esophageal-tracheobron-
chial reﬂex from distal esophageal exposure to gastric contents.33
The latter mechanism is thought to be evoked by an increased
frequency of transient lower esophageal sphincter relaxation
caused by gastric distension.34 Patterson et al. demonstrated higher
sputum levels of tachykinins in asthmatic or chronic cough patients
with acid reﬂux as demonstrated by 24 h esophageal pH moni-
toring than in those without acid reﬂux,35 which suggests that acid
perfusion into the distal esophagus promotes release of tachykinins
into the airway through the afferent nerve which may evoke
cough.35 Indeed, we previously found an association between GERD
symptoms and cough sensitivity to capsaicin inhalation in patients
with subacute or chronic cough15 and further demonstrated an
association between GERD symptoms and cough-speciﬁc QoL in
patients with CVA in the present study.
Several lines of evidence show the importance of gastroesoph-
ageal dysmotility in GERD-associated cough or chronic cough itself.
In a study of patients with GERD-associated cough, 38% of patients
had esophageal dysmotility as determined by esophageal
manometry.36 Among 42 patients with GERD-related cough who
Fig. 1. The association between the LCQ scores and cough VAS or cough numeric scores in patients with cough variant asthma. Associations of cough VAS and cough numeric scores
of the LCQ were plotted.
Table 2
The relationships between the LCQ scores and clinical variables on univariate
regression analysis.
Variables Estimates 95% C.I. p
value
Gender, females 0.78 1.34; 0.22 0.006
Log disease duration, months 0.35 1.02; 0.32 0.31
Age, years old 0.02 0.01; 0.05 0.29
Body mass index, kg/m2 0.02 0.17; 0.13 0.79
Smoking, ex-smoking 0.64 0.04; 1.32 0.066
Log FEV1, L 3.15 0.55; 6.86 0.095
%FEV1, % pred 0.01 0.01; 0.04 0.31
Log FEV1/FVC, % 2.90 14.9; 9.07 0.63
Log fractional exhaled nitric oxide at 50 ml/s,
ppb
0.94 1.28; 3.16 0.41
Log Dmin, unit 0.14 0.99; 1.26 0.81
Blood eosinophil, mL 0.001 0.002;
0.005
0.40
Atopic disposition 0.68 1.75; 0.38 0.21
Log total IgE, IU/ml 0.63 1.39; 0.12 0.10
Antigen speciﬁc IgE, positive e e e
Mixed gramineaes pollens 0.61 1.78; 0.56 0.31
Mixed moulds 0.18 1.81; 1.44 0.82
Mixed weed pollens 1.49 3.27; 0.29 0.10
House dust 1.17 2.29; 0.05 0.041
Dermatophagoides pteronyssinus 1.07 2.20; 0.05 0.061
Japanese cedar pollen 1.11 2.14; 0.08 0.034
Dog dander 0.61 2.35; 1.14 0.49
Cat dander 1.58 3.41; 0.25 0.091
Trichophyton rubrum 0.48 2.18; 1.22 0.58
Number of sensitized allergen 0.26 0.49; 0.02 0.032
FSSG, total scores 0.08 0.15; 0.00 0.050
Reﬂux-related symptoms domain 0.09 0.23; 0.05 0.23
Dysmotility symptoms domain 0.18 0.32; 0.04 0.014
FSSG, the Frequency Scale for the symptoms of gastroesophageal reﬂux.
Table 3
Multivariate regression analysis of clinical indices that contribute to the LCQ scores.
Variables Estimates 95% C.I. p value
Gender, females 0.82 1.54; 0.11 0.024
Log FEV1, L 2.29 2.54; 7.12 0.35
Log total IgE, IU/ml 0.16 1.51; 0.58 0.38
Antigen speciﬁc IgE, positive e e e
Mixed weed pollens 2.00 4.70; 0.69 0.14
House dust 3.17 7.92; 1.58 0.19
Dermatophagoides pteronyssinus 0.98 3.80; 5.76 0.69
Japanese cedar pollen 1.29 2.82; 0.24 0.097
Cat dander 0.84 3.11; 1.43 0.46
Number of sensitized allergen 0.47 0.34; 1.28 0.26
Dysmotility symptoms domain 0.23 0.30; 0.02 0.026
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responded to proton-pump inhibitors, 24 patients responded to
monotherapy with proton-pump inhibitor, while 18 patients
required additional prokinetic agents (metoclopramide or cis-
apride) for the resolution of cough.11 Furthermore, a cross-sectional
survey of the prevalence of chronic cough in the community in the
United Kingdom revealed that irritable bowel syndrome and
regurgitation, but not heartburn, were strong predictors for chronic
cough, in addition to smoking and lower social class.12 According to
a new disease concept of chronic cough termed “cough hypersen-
sitivity syndrome”, upregulation of intrinsic cough reﬂex triggered
by common causes of chronic cough was fundamental feature of
the pathophysiology of chronic cough.37 Morice et al. advocated
Table 4
Univariate and multivariate regression analysis of clinical indices that contribute to the LCQ scores adjusted by gender.
Variables Univariate analysis Multivariate analysis
Estimates 95% C.I. p value Estimates 95% C.I. p value
Log disease duration, months 0.39 1.05; 0.27 0.31
Age, years old 0.02 0.004; 0.05 0.094 0.001 0.03; 0.03 0.91
Body mass index, kg/m2 0.04 0.19; 0.11 0.62
Smoking, ex-smoking 0.41 0.29; 1.11 0.25
Log FEV1, L 0.13 4.89; 4.63 0.96
%FEV1, % pred 0.01 0.01; 0.04 0.31
Log FEV1/FVC, % 3.8 15.6; 7.96 0.52
Log fractional exhaled nitric oxide at 50 ml/s, ppb 0.12 2.14; 2.38 0.91
Log Dmin, unit 0.02 1.04; 1.09 0.96
Blood eosinophil, mL 0.001 0.002; 0.004 0.64
Atopic disposition 0.98 2.03; 0.08 0.069
Log total IgE, IU/ml 0.76 1.50; 0.01 0.047 0.45 1.49; 0.59 0.39
Antigen speciﬁc IgE, positive e e e
Mixed gramineaes pollens 0.77 1.93; 0.38 0.19
Mixed moulds 0.46 2.07; 1.14 0.57
Mixed weed pollens 1.88 3.64; 0.13 0.036 1.63 4.23; 0.96 0.22
House dust 1.78 2.91; 0.64 0.002 2.56 7.30; 2.18 0.29
Dermatophagoides pteronyssinus 1.67 2.81; 0.54 0.004 0.80 3.98; 5.58 0.74
Japanese cedar pollen 1.42 2.44; 0.41 0.006 1.21 2.75; 0.32 0.12
Dog dander 1.04 2.78; 0.69 0.24
Cat dander 1.64 3.44; 0.15 0.072 0.73 3.01; 1.55 0.53
Trichophyton rubrum 0.64 2.32; 1.03 0.45
Number of sensitized allergen 0.36 0.60; 0.13 0.003 0.27 0.43; 0.98 0.44
FSSG, total scores 0.07 0.14; 0.004 0.063
Reﬂux-related symptoms domain 0.08 0.22; 0.06 0.27
Dysmotility symptoms domain 0.17 0.31; 0.03 0.017 0.16 0.30; 0.02 0.026
FSSG, the Frequency Scale for the symptoms of gastroesophageal reﬂux.
Table 5
Factors contributing to the LCQ scores when patients who responded to treatment of GERD were excluded from analysis (n ¼ 162).
Variables Univariate analysis Multivariate analysis
Estimates 95% C.I. p value Estimates 95% C.I. p value
Gender, females 0.85 1.42; 0.27 0.004 1.04 1.62; 0.46 0.0005
Log disease duration, months 0.27 0.96; 0.42 0.44
Age, years old 0.02 0.007; 0.05 0.13
Body mass index, kg/m2 0.01 0.15; 0.18 0.87
Smoking, ex-smoking 0.64 0.05; 1.34 0.069
Log FEV1, L 2.99 0.79; 6.78 0.12
%FEV1, % pred 0.02 0.005; 0.05 0.11
Log FEV1/FVC, % 4.05 16.1; 8.03 0.51
Log fractional exhaled nitric oxide at 50 ml/s, ppb 1.08 1.20; 3.35 0.35
Log Dmin, unit 0.17 1.03; 1.38 0.78
Blood eosinophil, mL 0.002 0.002; 0.005 0.33
Atopic disposition 0.78 1.89; 0.33 0.17
Log total IgE, IU/ml 0.63 1.42; 0.15 0.11
Antigen speciﬁc IgE, positive e e e
Mixed gramineaes pollens 0.55 1.76; 0.64 0.36
Mixed moulds 0.04 1.75; 1.68 0.97
Mixed weed pollens 1.35 3.20; 0.50 0.15
House dust 1.18 2.33; 0.03 0.045 2.33 6.97; 2.30 0.32
Dermatophagoides pteronyssinus 1.08 2.23; 0.08 0.067 1.13 3.57; 5.84 0.63
Japanese cedar pollen 1.16 2.23; 0.10 0.032 1.10 2.58; 0.39 0.15
Dog dander 0.48 2.34; 1.37 0.61
Cat dander 1.62 3.47; 0.22 0.084 0.85 3.16; 1.47 0.50
Trichophyton rubrum 0.49 2.35; 1.37 0.61
Number of sensitized allergen 0.26 0.51; 0.02 0.037 0.08 0.46; 0.62 0.777
FSSG, total scores 0.07 0.15; 0.01 0.095
Reﬂux-related symptoms domain 0.07 0.22; 0.08 0.33
Dysmotility symptoms domain 0.16 0.31; 0.01 0.034 0.15 0.29; 0.007 0.040
FSSG, the Frequency Scale for the symptoms of gastroesophageal reﬂux.
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that gaseous non-acid reﬂex that was undetectable by currently
available technique may play fundamental role in the pathophysi-
ology of “cough hypersensitivity syndrome”.38 Current ﬁnding, the
impairment of cough-speciﬁc QoL in patients with CVA by the
presence of gastroesophageal dysmotility, may support Morice's
hypothesis. However, the effect of gastroesophageal dysmotility on
the pathophysiology of “cough hypersensitivity syndrome” in pa-
tients with CVA remains to be further clariﬁed.
Previous studies showed that levels of FEV1, AHR, and FeNO
correlated with wheezing39e42 and dyspnea39,43,44 in patients with
asthma. Meanwhile, there were no association of FEV1,7,39
AHR,7,40,41 or FeNO7 with cough frequency, as well as those with
cough-speciﬁc QoL8 in patients with asthma. In the current study,
patients with CVA showed no relationships between these 3 indices
and cough-speciﬁc QoL. We previously found an association be-
tween plasma levels of substance P and methacholine AHR in pa-
tients with asthmatic cough.45 Since airway tachykinins may play
potential roles in asthma or chronic cough associated with reﬂux,35
and upregulation of neuronal mechanisms involving transient re-
ceptor potential (TRP) nociceptors such as TRPV-1 is considered a
key feature of cough hypersensitivity syndrome,37 the relationship
between cough in CVA or asthma and neurogenic airway inﬂam-
mation should be further examined in future studies.
It is well known that chronic cough is more prevalent in females
than in males.46 In fact, in patients with chronic cough30,47 and
healthy volunteers,48 females showed increased cough sensitivity
to capsaicin and citric acid than males. However, there are con-
ﬂicting ﬁndings about gender difference on cough-speciﬁc QoL.29,30
Birring et al. also demonstrated a signiﬁcant association between
LCQ scores and female gender,29 whereas Kelsall et al. failed to
show a gender difference in LCQ scores.30 Kelsall et al. found that
females coughed more frequently during the nighttime (p < 0.01)
and for 24 h (p ¼ 0.01), but not during the daytime (p ¼ 0.06), than
males.30 This might explain the lack of sex difference in cough-
speciﬁc QoL examined by the LCQ in Kellsall's study.29 The pre-
sent study conﬁrmed the Birring's study that cough-speciﬁc QoL
examined by the LCQ were impaired more in female patients with
CVA than in male patients.
This study involves several limitations. First, cough frequency
was not objectively measured using a cough monitor device.
However, earlier reports have already conﬁrmed moderate corre-
lations between cough frequency and the LCQ scores (r ¼ 0.547
and 0.628). Second, the symptoms of GERD were merely evalu-
ated by the FSSG questionnaire without the use of objective
methods such as using 24-h intraesophageal pH monitoring,
manometry, or impedance monitoring. Associations between LCQ
scores and these objective measures of GERD could not be
addressed in this study. However, current guideline clearly has
noted that these maneuver are considered when empiric treatment
for GERD fails.49 In addition, the GERD questionnaires, including
the FSSG have been used in several studies to evaluate the symp-
toms of GERD in respiratory research ﬁeld.15e18 Third, the LCQ
questionnaire that was translated into Japanese by forward and
backward translation method according to the standard protocol24
was used instead of original version of the LCQ. We thus evaluated
the reliability and validity of the Japanese version of the LCQ. Jap-
anese version of the LCQ showed high internal consistency and
signiﬁcant correlation with other instruments utilized to assess
cough severity and frequency. Indeed, values of Cronbach a coef-
ﬁcient and correlation coefﬁcients between the LCQ and cough
VAS/numeric scores obtained from current study were similar to
those from the original report.23 Therefore, as was the original
LCQ,23 the Japanese version of the LCQ can be considered valid as an
instrument to assess cough-speciﬁc QoL. However, we have not
checked retest repeatability for the Japanese version of the LCQ.
Forth, although allergic rhinitis/chronic rhinosinusitis are also
known as most common cause of chronic cough and is involved in
the pathophysiology of cough hypersensitivity syndrome together
with asthma and GERD, we did not evaluate an association between
sinonasal symptoms and cough-speciﬁc QoL because of the lack of
validated questionnaires about sinonasal symptoms. Recently,
sinonasal outcome test-22, a validated questionnaire about rhinitis
and sinusitis, is developed to assess symptoms of rhinitis and
sinusitis and is used in clinical and research ﬁelds of respiratory
medicine.50 Further study is required whether sinonasal symptoms
assessed by validated tools contribute to the impairment of cough-
speciﬁc QoL in patients with CVA.
In conclusion, the present ﬁndings suggest that gastroesopha-
geal dysmotility independently affects the impairment of cough-
speciﬁc QoL in patients with CVA as measured by Japanese
version of the LCQ, which showed very high reliability compatible
to the original one. Dysmotility symptoms might potentially be a
therapeutic target in patients with CVA whose cough is intractable
to anti-asthma treatment.51 Further prospective studies are needed
to determine whether speciﬁc treatment of gut dysmotility affects
cough or cough-speciﬁc QoL of CVA patients to further clarify the
involvement of gut dysmotility in the pathophysiology of CVA.
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